Suven Life Sciences secures Product Patents in China & Eurasia

Shalini | Myequity news | Date : 29-08-2018 13:30:00 IST

Suven Life Sciences Ltd (Suven), a biopharmaceutical company, today announced that the grant of one (1) product patent from China (CN105873920) and one (1) productpatent from Eurasia (029951) corresponding to the New Chemical Entity for the treatmentof disorders associated with Neurodegenerative diseases and patents are valid through 2034.

The granted claims of the patents include the class of selective 5-HT4 compoundsrespectively and are being developed as therapeutic agents for neurodegenerativedisorders such as for the treatment of cognitive impairment associated withneurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivitydisorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorderslike Narcolepsy etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules inCNS arena that are being developed for cognitive disorders with high unmet medical needwith huge market potential globally” says Venkat Jasti, CEO of Suven.

About Suven Life Sciences:

Suven Life Science is a biopharmaceutical company focused on discovering, developing andcommercializing novel pharmaceutical products, which are first in class or best in class CNStherapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoingSUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010, Phase 1commenced SUVN-911 and Phase 1 ready SUVN-I6107.

In addition to these clinical compounds the Company has nine (9) internally-discoveredtherapeutic drug candidates currently in various stages of pre-clinical development targetingconditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s diseaseand pain.


More from Myequity